搜尋
Inhibikase Therapeutics Inc
IKT添加自選
1.990USD
+0.050+2.58%
收盤 07/02, 13:00（美東）報價延遲15分鐘
262.74M總市值
虧損本益比TTM
關於 Inhibikase Therapeutics Inc 公司
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Inhibikase Therapeutics Inc簡介
公司代碼IKT
公司名稱Inhibikase Therapeutics Inc
上市日期Dec 23, 2020
CEOIwicki (Mark T)
員工數量15
證券類型Ordinary Share
年結日Dec 23
公司地址1000 N. West Street, Suite 1200
城市WILMINGTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編19801
電話13022953800
網址https://www.inhibikase.com/
公司代碼IKT
上市日期Dec 23, 2020
CEOIwicki (Mark T)
Inhibikase Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
Mr. Roberto Bellini
Mr. Roberto Bellini
Independent Director
Independent Director
--
-100.00%
Mr. David Canner, Ph.D.
Mr. David Canner, Ph.D.
Independent Director
Independent Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Managing Director of LifeSci Advisors
Managing Director of LifeSci Advisors
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
President, Head - Research and Development
President, Head - Research and Development
676.56K
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
510.60K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
403.18K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
常見問題
Inhibikase Therapeutics Inc的前五大股東是誰？
Inhibikase Therapeutics Inc的前五大股東如下：Dr. Christopher H. (Chris) Cabell, M.D.
有多少機構持有Inhibikase Therapeutics Inc(IKT)的股份？
截至2026Q1，共有152家機構持有Inhibikase Therapeutics Inc的股份，合計持有的股份價值約為103.21M，占公司總股份的78.17% 。與2025Q4相比，機構持股有所增加，增幅為43845693.00。